anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To obtain a viable bacterium preparation containing a viable bacteri um and chlorella powder as an excipient, useful for medicines, foods, etc., and capable of enhancing the survival rate of bacterial cells after prepared. CONSTITUTION: The viable bacterium preparation contains a viable bacterium, preferably lactobacillus, as a main ingredient and 60-90wt.% of chlorella powder as an excipient. The chlorella powder has following properties; a particle degree distribution: particle sizes of <=149μm: 80-98%, particle sizes of 150-250μm: 2-20%; a bulk density of 0.37±0.05; a tap density: 0.46±0.05g/cm<3> ; and an angle of repose: 42±5 degree. The addition of a conventional binder such as crystalline cellulose, calcium carboxymethylcellulose or α-starch to the chlorella in an amount of 3-20wt.% gives tablets high in hardness without killing the viable lactobacillus. If necessary, a lubricant, a perfume, a pigment, a pharmacodynamic ingredient, etc., may be added to prepare a formulation. The tabletting enables to prevent abrasion and defects generated on storage or carriage.
Cystic fibrosis (CF) is caused by the cystic fibrosis transmembrane conductance regulator (CFTR) gene mutation and represents one of the most frequent and lethal inherited disease in Caucasian. However, thanks to better treatments that slow down the progression of pulmonary disease, the median life expectancy has reached 41 years and there are nowadays more CF patients older than 18-year-old than younger. Chronic lung disease is the main manifestation and represents more than 90% of CF morbidity and mortality. However, there is a need for biomarkers more sensitive than clinical and functional findings for a personalized management of patients. Computed tomography (CT), owing to its high spatial resolution and contrast, is the standard of reference in imaging for depicting lung structural alterations. But CT is an ionizing technique, rising concern in cancer risk associated to cumulated radiation dose. To date, Magnetic Resonance Imaging (MRI) is a radiation-free technique which has been demonstrated to add meaningful functional information that cannot be reached using CT. Recent advances in 3-dimensional ultra-short echo time (3D-UTE) imaging have been shown promising to improve lung MR imaging quality. A clear delineation between airway wall and lumen was obtained, thanks to submillimeter voxel size, enabling readers to estimate both bronchial thickening and dilatation with very good concordance with CT, independently from the magnitude of score. The combination of pulse sequence may rather benefit from the potential of MRI to get more complete insight into inflammatory processes by combining several contrasts, as compared to other ionizing methods. Novel MR methods have been shown promising in assessing lung changes with high resolution and therefore could be proposed instead of CT for radiation- free repeated, life-long follow-up
Patients with hepatocellular carcinoma greater than 1 cm in size. All patients from an ultrasound screening programme who have been diagnosed with a nodule larger than 1 cm and referred to our centres will be included in this group. They will then be excluded of this group if the diagnosis of hepatocellular carcinoma is not retained according to the radiological or histological reference diagnostic standards (gold standard).
Clinical trials in adults and children suggest that SQV-SGC has advantages over other protease inhibitors in terms of tolerability, safety, and effectiveness in patients who have failed therapy with other protease inhibitors. \[AS PER AMENDMENT 11/24/99: Pharmacokinetic data from this study demonstrate lower than expected plasma SQV exposures, particularly in Arm 1. Based on these data, patients in the study will be offered the opportunity to adjust their doses. Ritonavir added to the Arm 1 regimen is expected to significantly increase SQV-SGC plasma levels and allow twice-daily dosing for SQV-SGC.\]

Patients are randomized to one of two study arms. Patients in Arm 1 receive SQV-SGC plus two \[AS PER AMENDMENT 11/24/99: one or two\] NRTIs of choice. Patients in Arm 2 receive SQV-SGC plus NFV plus one or two NRTIs of choice. All participants are evaluated by physical examinations and laboratory tests during the study and are followed for incidence of death, cancer, or fetal abnormality. NRTIs are not provided as part of this study. \[AS PER AMENDMENT 11/24/99: This study is closed to accrual. All subjects on follow-up (Cohort 1) are given the option of either discontinuing participation in ACTG 397 or participating in the next phase of the study (version 2.0). Those electing to continue participation constitute Cohort 1A. The adjusted Arm 1 regimen consists of SQV-SGC plus ritonavir plus one or two NRTIs. Ritonavir is not provided as part of this study. The Arm 2 regimen study drugs have not changed but the maximum allowable dose of SQV-SGC has increased from 1,200 mg twice-daily to 1,600 mg twice-daily. Participants continue to be followed with physical examinations and laboratory evaluations that include an intensive pharmacokinetics study on Day 14 of the new regimen.\]
The invention successfully constructs the light-excited multilevel nano-carrier with the anti-vascularization and oxygen supply capacity through the electrostatic adsorption of PEG-PCL-TSPBA, indocyanine green and 1-methyl-2-pyridone. The nano-carrier shows excellent light stability and ROS reaction capability. After exposure to 785nm radiation, the nanocarriers in the tumor can undergo a multi-stage reaction, generating a thermal effect and three ROS. High heat induces 1-methyl-2-pyridone to release oxygen, which is helpful for relieving the hypoxia of tumors and promoting the generation of ROS. In addition, ROS can also promote reactive rupture of nanocarriers when inducing photodynamic therapy, rapidly increasing the drug concentration at the tumor site. The self-assembled nanoparticles provided by the invention show excellent treatment effect on MNNS/HOS osteosarcoma mice, and may also be a good treatment strategy on the treatment of hypoxic tumors.
PCT No. PCT/US94/13606 Sec. 371 Date Jul. 22, 1996 Sec. 102(e) Date Jul. 22, 1996 PCT Filed Nov. 22, 1994 PCT Pub. No. WO95/14460 PCT Pub. Date Jun. 1, 1995Patients are treated with 24-hour oral sustained release opioid formulations which, upon administration, provide an initially rapid opioid absorption such that the minimum effective analgesic concentration of the opioid is more quickly achieved. These sustained release opioid formulations include an effective amount of at least one retardant material to cause said opioid analgesic to be released at a such a rate as to provide an analgesic effect after oral administration to a human patient for at least about 24 hours, and are characterized by providing an absorption half-life from 1 to about 8 hours. A method of titrating a human patient utilizing these sustained release opioid formulations is also disclosed.
Participants will receive 20 mg/kg loading dose of caffeine citrate on the first day of life and after that 5-10 mg/kg maintenance dose each day. On this arm, the participants will receive 20 mg/kg caffeine dose once again before the planned extubation.
FIELD: food industry. ^ SUBSTANCE: food product is characterised by a low content of glucose - up to 5% or an utter absence of it, balanced content of fat of less than 10%. The product includes a mixture of phytosterol ethers and/or phytostanol ethers (PS-E) with 1,3-diglycerides (DAG), not necessarily disperse or dissolved in food oil or fat. Moreover, content of PS-E exceeds that of DAG. ^ EFFECT: invention enables to produce a product controlling glucose exchange and insulin secretion suitable for prevention and treatment of conditions caused by diabetes to patients suffering from diabetes or in people predisposed to it. ^ 18 cl, 12 dwg, 4 tbl, 18 ex
A condition visualization system includes a first acquisition unit, an estimation unit, a processing unit, an output unit, a second acquisition unit, and a correction information generation unit. The first acquisition unit acquires a user's biometric information. The estimation unit obtains, based on the biometric information, an estimated value representing the user's mental and physical condition. The processing unit generates, based on the estimated value, mental and physical condition information. The output unit outputs the mental and physical condition information to a display unit. The second acquisition unit acquires a subjective value with respect to the user's mental and physical condition. The correction information generation unit generates correction information by using a plurality of data sets, each including the estimated value and the subjective value. The processing unit generates the mental and physical condition information by making correction to the estimated value based on the correction information.
PURPOSE:To obtain the subject release rate regulator, containing sucrose ester of a fatty acid as an active ingredient and suitable especially for operating a direct tableting method. CONSTITUTION:A release rate regulator obtained by blending sucrose ester of a fatty acid which is sucrose ester of an 8-20C medium to higher fatty acid (e.g. caprylic acid, lauric acid, palmitic acid, stearic acid, behenic acid or oleic acid) that is a mono-, di- or triester mainly related to three primary hydroxyl groups of sucrose or a mixed ester thereof in an amount of >=10wt.% based on a composition to be tableted. If effects as a binder are especially expected, a sucrose ester having 8-15 HLB is used and blended in an amount of 10-25wt.% based on the total composition to be tableted. If the regulator is used as an excipient, an ester having >=6 HLB is used and blended in an amount of 15-50wt.%. The elution rate of the main drug can be controlled by suitably selecting the HLB and blended amount of the above-mentioned ester and the regulator is effective in keeping the blood level of the main drug at a prescribed level throughout a desired period.
Psychological Intervention. Participants are asked to work on a brief paper-and-pencil task that has been shown to induce an Implemental Mindset according to the Mindset theory of action phases (Gollwitzer \& Keller (2016). Mindset Theory. In: V. Zeigler-Hill, T.K. Shackelford (eds.), Encyclopedia of Personality and Individual Differences. New York: Springer).
<P>PROBLEM TO BE SOLVED: To provide a dermatological composition including co-enzyme Q as an active ingredient and provide a therapeutic agent that has high safety and high effectiveness.  <P>SOLUTION: This dermatological composition includes oxidized co-enzyme Q and or reduced co-enzyme Q as an active ingredient. In this composition, the total of the oxidized co-enzyme Q and the reduced co-enzyme Q is 0.01 to 99 wt.%. Further, the following compositions using this dermatological composition can be provided: a therapeutic composition for skin diseases; a cosmetic composition; skin health care composition; and bath agent composition. A therapeutic method for patients with skin diseases by applying the dermatological composition or another therapeutic method for patients with skin diseases by applying this therapeutic composition and other skin therapeutic compositions than the oxidized or reduced co-enzyme Q in parallel.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
These subjects will undergo another "in the sleep-lab" diagnostic polysomnography that is identical to the one that they had for standard of care to diagnose OSA. Within one hour prior to the research polysomnography the subjects will be given oxytocin (40 IU) intranasally. Outcome measures will be assessed.
Group-based CBT-H consists of 6 weekly sessions that are conducted in groups with a study therapist using live videoconferencing or in-person. Each session is expected to last about 45 to 60 minutes. The treatment package consists of the same cognitive and behavioral modules as the individual CBT-H. However, participants are also provided the opportunity to share their experiences and provide peer support in the group format.
The present invention relates to psoriasis and to the treatment and prevention thereof. Specifically, a biomarker of psoriasis has been identified, namely Flightless I. Accordingly, the present invention provides methods for the treatment and/or prevention of psoriasis by decreasing the expression and/or activity of Flightless I. Methods of diagnosing psoriasis are also provided together with methods of determining susceptibility to psoriasis. Pharmaceutical compositions including agents that decrease the expression and/or activity of Flightless I are also provided for the treatment and/or prevention of psoriasis. Finally, kits for diagnosing psoriasis or for determining susceptibility to psoriasis are encompassed by the present invention.
Subjects will exercise for 12 weeks (3 times weekly, with each total workout being approximately 60 minutes in length). The exercise protocol will incorporate elements of mindfulness, cardiovascular strengthening, and controlled breathing.
The present invention relates to collateral activating oil. The present invention is characterized in that the present invention is a medicament made of raw materials in a quality ratio: 28.9 to 39.1 of menthol, 25.5 to 34.5 of methyl salicylate, 7.5 to 16.5 of turpentine, 7 to 13 of lavender oil, 6.0 to 12.0 of camenthol and 3 to 6 of olive oil. The present invention also relates to a preparation method for the collateral activating oil, which comprises steps: the menthol, the methyl salicylate, the turpentine, the camenthol, etc. are stirred and blended; then the lavender oil and the olive oil are added for mixing and blending. The collateral activating oil of the present invention has the functions of relaxing tendons, activating collaterals, expelling wind and dissipating blood stasis, the effect taking rate for rheumatic symptoms is greater than 90%, and the effective rate for eliminating swellings, absorbing clots, etc. is higher than 91.5%.
Participants randomized to FBT + EC parent group condition will also receive FBT as part of their standard of care. In addition to FBT, they will receive 10 additional, weekly, parent group sessions (each session is 60 minutes, 6-8 group members), within a 3-month time frame to account for cancellations. The EC intervention is designed to reduce expressed emotion (e.g., critical comments) and increase parental warmth. The intervention includes emotional awareness and emotion regulation skills for parents, and emotion communication skills for parents to use with their teens undergoing FBT including active listening, emotion support, labeling emotions, and coping with emotions. The structure of EC parent group sessions will begin with review of homework as applicable, a didactic component to teach new skills, followed by role plays between parents in the group and interventionist, and live coaching and feedback from the interventionist.
NEW MATERIAL:The compound of formula I. USE:An agent for increasing calcium level in serum. Useful as a remedy for osteomalacia and osteoporosis. PREPARATION:The objective compound can be produced by reducing 1alpha,25- dihydroxyvitamin D3-26,23-lactone of formula II with a metal hydride (e.g. isobutylaluminum hydride and aluminum borohydride) in an inert organic solvent (e.g. ether and toluene).
This exclusive blend of scientifically substantiated ingredients has been demonstrated to contribute to the reduction of body weight and aid the sustainability of weight loss by providing a healthy, hunger-free weight management system. iofibrewater, makes fibre and gut health simple and refreshing. Each 500 ml bottle of ió fibrewater provides 20%\* of your recommended daily fibre intake and 100%\* of your daily prebiotic fibre intake with minimal calories and carbohydrates, making us suitable for people on a variety of diets. ió fibrewater is a functional water infused with prebiotic fibre (aka prebiotics), which leads to sub-optimal gut health and often the onset of digestive disorders. By adding more prebiotic fibre to our diet, we can quickly change the environment in our gut for the better healthy living.
Botulinum toxin (BT) injections are commonly used to treat various cosmetic, muscular, anesthetic, and neurologic pathologies. In 2012, one study suggested that a combination of zinc and phytase supplementation could increase the duration and degree of effects of botulinum neurotoxin type A (BoNTA). However, this study was met with scientific skepticism due to concerns of financial conflicts of interest, unmasking the study too early, and ambiguity of the dosage of zinc used. In 2021, a new study with 25 patients receiving BoNTA injections for the treatment of excessive gingival display (EGD), showed that zinc supplementation prolonged the effect of BoNTA with statistical significance. There has been no further studies or commentary since these latest results were published. The purpose of this study is to test if the effect of zinc supplementation on BoNTA can be replicated and also translated to a different disease process that is also treated with BT-spasmodic dysphonia (SD). If positive effects are discovered, this would strengthen the preliminary results of the 2021 study, encourage future larger studies on the same hypothesis, and, ultimately, could lead to reducing the burden of disease for patients with SD and any other condition that is treated with BT injections.
Immune cells play a vital role in the development and progression of lung cancer (LC). We aimed to explore the causal role of immune cells in LC with Mendelian randomization (MR) study. Summary statistic data used in the study were obtained from genome-wide association studies (GWAS). A comprehensive two-sample MR was carried out to explore the causal role of 731 immune cell traits (ICTs) in LC, Non-small cell lung cancer (NSCLC), and Small cell lung cancer (SCLC). An inverse-variance weighted (IVW) approach was applied to present the MR estimates. The heterogeneity test was performed using Cochran's Q statistic. MR-Egger intercept test and MR-PRESSO were utilized for the pleiotropy test. MR showed that 15, 31, and 11 ICTs had protective effects on LC, NSCLC, and SCLC, respectively, and 12, 31, and 11 ICTs had adverse effects on LC, NSCLC, and SCLC, respectively. Of note, CD3 on CD28+ CD4+ in the Treg panel could significantly increase the risk of LC, as well as NSCLC and SCLC. Moreover, the MR results revealed that LC was vital in IgD on IgD+ in the B cell panel and NSCLC on CCR2 on CD14- CD16- in the Monocyte panel. Our study revealed multiple close connections between immune cells and LC.
The repair of skin defects is a common problem for reconstructive surgeons.Soft tissue expansion is a widely used technique for the repair of skin defects. Early expansion-related complications such as skin thinning, telangiectasia, and striae may result in expansion failure and ultimately jeopardize final outcome. In the past years, discontinuation of the expansion procedure was the only therapeutic option, when early alarm signs such as semitransparent appearance and telangiectasia of the expanded skin were encountered. We aimed to overcome these complications by therapeutic fat grafting to prevent skin necrosis and enable continuation of the expansion procedure.

Patients undergoing soft tissue expansion treatment for resurfacing skin lesions including scars and nevi that required therapeutic intervention due to early complication signs were included in this study. Patients were randomly divided into treatment group using autologous fat grafting and control group with discontinued expansion and expectant management. The treatment group received autologous fat transfer to the expanded skin.
BACKGROUND: Clinical trials of direct oral anticoagulants (DOAC) are scarce and inconclusive in patients who are receiving dialysis, for whom DOAC are not labelled in Europe. In a French nationwide registry study of patients on chronic dialysis, we compared the effectiveness and safety of off-label DOAC use vs approved vitamin K antagonist (VKA).
METHODS: Data on patients on dialysis were extracted from the French Renal Epidemiology and Information Network (REIN) registry and merged with data from the French national healthcare system database (Système National des Données de Santé, SNDS). Patients on dialysis who had initiated treatment with an oral anticoagulant between 1 January 2012 and 31 December 2020, were eligible for inclusion. The primary safety outcome was the occurrence of major bleeding events and the primary effectiveness outcome was the occurrence of thrombotic events. Using propensity score-weighted cause-specific Cox regression, we compared the safety and effectiveness outcomes for DOAC and VKA.
RESULTS: A total of 8954 patients received an oral anticoagulant (483 DOAC and 8471 VKA) for the first time after the initiation of dialysis. Over a median (interquartile range) follow-up period of 1.7 (0.8-3.2) years, 2567 patients presented a first thromboembolic event and 1254 patients had a bleeding event. After propensity score adjustment, the risk of a thromboembolic event was significantly lower in patients treated with a DOAC than in patients treated with a VKA {weighted hazard ratio (wHR) [95% confidence interval (CI)] 0.66 (0.46; 0.94)}. A non-significant trend toward a lower risk of major bleeding events was found in DOAC-treated patients, relative to VKA-treated patients [wHR (95% CI) 0.68 (0.41; 1.12)]. The results were consistent across subgroups and in sensitivity analyses.
CONCLUSIONS: In a large group of dialysis patients initiating an oral anticoagulant, the off-label use of DOACs was associated with a significantly lower risk of thromboembolic events and a non-significantly lower risk of bleeding, relative to VKA use. This provides reassurance regarding the off-label use of DOACs in people on dialysis.
Nonalcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases worldwide. In recent years, a new terminology and definition of metabolic dysfunction-associated fatty liver disease (MAFLD) has been proposed. Compared to the NAFLD definition, MAFLD better emphasizes the pathogenic role of metabolic dysfunction in the development and progression of this highly prevalent condition. Metabolic disorders, including overweight/obesity, type 2 diabetes mellitus (T2DM), atherogenic dyslipidemia and hypertension, are often associated with systemic organ dysfunctions, thereby suggesting that multiple organ damage can occur in MAFLD. Substantial epidemiological evidence indicates that MAFLD is not only associated with an increased risk of liver-related complications, but also increases the risk of developing several extra-hepatic diseases, including new-onset T2DM, adverse cardiovascular and renal outcomes, and some common endocrine diseases. We have summarized the current literature on the adverse effect of MAFLD on the development of multiple extrahepatic (cardiometabolic and endocrine) complications and examined the role of different metabolic pathways and organ systems in the progression of MAFLD, thus providing new insights into the role of MAFLD as a multisystem metabolic disorder. Our narrative review aimed to provide insights into potential mechanisms underlying the known associations between MAFLD and extrahepatic diseases, as part of MAFLD as a multisystem disease, in order to help focus areas for future drug development targeting not only liver disease but also the risk of extrahepatic complications.
PURPOSE: A fusion protein of 3D8 scFv PTD(Protein Transduction Domain) and T cell epitope linked to the amino acid terminal thereof are provided to cause antigen cross presentation and to ensure excellent anticancer and antiviral effects. CONSTITUTION: A fusion protein contains 3D8 scFv PTD and T cell epitope which is linked to the amino acid terminal thereof. 3D8 scFv PTD is denoted by sequence number 1. The T cell is an OVA(ovalbumin) peptide or a part thereof. A vaccine composition contains the fusion protein as an active ingredient. The vaccine composition enhances the activity of cytotoxic T cells. The vaccine composition prevents or treats cancer and viral infection.